Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495288 | 0.95 | HTT (0.57) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL16960540 | 0.90 | HTT (0.48) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL11442603 | 0.90 | TSHR (0.55) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL18538952 | 0.88 | HTT (0.47) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL13598125 | 0.87 | TSHR (0.65) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL22133013 | 0.87 | HTT (0.46) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL1069365 | 0.86 | HTT (0.48) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL8570170 | 0.86 | HTT (0.48) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL18416742 | 0.86 | HTT (0.48) | HTTPOLBTSHRCYP19A1LMNA | |
| SCHEMBL7786787 | 0.86 | HTT (0.58) | HTTPOLBTSHRCYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-3325482-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9890179-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050986-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-0566783-A1 | Process for the production of nitrodiarylamines | AKZO N.V. (NL) | 1993-10-27 | — | — | EP | disclosed |
| US-3962307-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | HTT 3221/4885POLB 1906/4885TSHR 713/4885 |
| US-20170050986-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | HTT 3221/4885POLB 1906/4885TSHR 713/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | HTT 857/4885POLB 3723/4885TSHR 655/4885 |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | HTT 3221/4885POLB 1906/4885TSHR 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.